AMA submission on TGA proposals ​for naming biological medicines

The AMA recommends the TGA maintains the status quo for differentiating between biological and biosimilar medicines for monitoring and reporting purposes at this stage, until international regulators have implemented their own systems and Australia can learn from their experience.